DK0998473T3 - Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse - Google Patents

Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse

Info

Publication number
DK0998473T3
DK0998473T3 DK98941342T DK98941342T DK0998473T3 DK 0998473 T3 DK0998473 T3 DK 0998473T3 DK 98941342 T DK98941342 T DK 98941342T DK 98941342 T DK98941342 T DK 98941342T DK 0998473 T3 DK0998473 T3 DK 0998473T3
Authority
DK
Denmark
Prior art keywords
phenyl
processes
preparation
crystal modification
pyrimidinamine derivative
Prior art date
Application number
DK98941342T
Other languages
Danish (da)
English (en)
Inventor
Bertrand Sutter
Hans Michael Buerger
Juerg Zimmermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4218028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0998473(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0998473T3 publication Critical patent/DK0998473T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Metallurgy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK98941342T 1997-07-18 1998-07-16 Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse DK0998473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH176497 1997-07-18
PCT/EP1998/004427 WO1999003854A1 (en) 1997-07-18 1998-07-16 Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Publications (1)

Publication Number Publication Date
DK0998473T3 true DK0998473T3 (da) 2004-02-02

Family

ID=4218028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98941342T DK0998473T3 (da) 1997-07-18 1998-07-16 Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse

Country Status (31)

Country Link
US (5) US6894051B1 (de)
EP (1) EP0998473B1 (de)
JP (1) JP3276359B2 (de)
KR (1) KR100450356B1 (de)
CN (1) CN1134430C (de)
AR (2) AR016351A1 (de)
AT (1) ATE251152T1 (de)
AU (1) AU740713B2 (de)
BR (1) BR9810920A (de)
CA (1) CA2296604C (de)
CO (1) CO4940418A1 (de)
CZ (1) CZ298531B6 (de)
DE (1) DE69818674T2 (de)
DK (1) DK0998473T3 (de)
ES (1) ES2209194T3 (de)
HK (1) HK1028599A1 (de)
HU (1) HU230185B1 (de)
ID (1) ID24093A (de)
IL (5) IL133906A0 (de)
MY (2) MY129772A (de)
NO (2) NO319486B1 (de)
NZ (1) NZ502295A (de)
PE (1) PE97899A1 (de)
PL (1) PL188348B1 (de)
PT (1) PT998473E (de)
RU (1) RU2208012C2 (de)
SK (2) SK286551B6 (de)
TR (1) TR200000060T2 (de)
TW (1) TW491845B (de)
WO (1) WO1999003854A1 (de)
ZA (1) ZA986362B (de)

Families Citing this family (343)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
CA2424470C (en) * 2000-10-27 2009-06-09 Novartis Ag Treatment of gastrointestinal stromal tumors
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
DE60232719D1 (de) * 2001-02-27 2009-08-06 Novartis Ag Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1704863A3 (de) * 2001-05-16 2010-11-24 Novartis AG Kombination von N-{5-[4-(4-Methyl-Piperazino-Methyl)-Benzoylamido]-2-Methylphenyl}-4-(3-Pyridyl)-2Pyrimidine-Amin mit einem Chemotherapeutikum
AU2005246965B2 (en) * 2001-05-16 2008-04-17 Novartis Ag Combination comprising N-{5-[4(4-methyl-piperazino-methyl)-bezoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
JP4477303B2 (ja) * 2001-05-16 2010-06-09 ノバルティス アーゲー Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
EP1466174B1 (de) 2001-06-14 2009-05-13 The Regents of the University of California Mutationen in der mit der resistenz gegenüber sti-571 assoziierten bcr-abl-tyrosinkinase
EP1408978A4 (de) * 2001-06-21 2005-07-13 Ariad Pharma Inc Neue phenylamino-pyrimidine und ihre verwendungszwecke
WO2003002108A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
EP1401413B1 (de) 2001-06-29 2006-11-22 AB Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
WO2003039550A1 (en) * 2001-09-20 2003-05-15 Ab Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
EP2017335B1 (de) 2001-10-05 2010-12-01 Novartis AG Mutante der kinase Domäne des ABL
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
US20040044405A1 (en) * 2001-10-25 2004-03-04 Wolff Matthew R. Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
AU2007201056B2 (en) * 2002-01-28 2010-06-10 Hyks-Instituutti Oy Treatment of rheumatoid arthritis using imatinib
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP2005523282A (ja) * 2002-02-22 2005-08-04 ザ・ガバメント・オブ・ザ・ユナイテッド・ステイツ・ザ・デパートメント・オブ・ベテランズ・アフェアーズ 精上皮腫を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミドの使用
CN1326577C (zh) * 2002-02-28 2007-07-18 诺瓦提斯公司 N－{5－[4－(4－甲基－哌嗪－1－基甲基)－苯甲酰氨基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺涂层的支架
AU2003233946A1 (en) * 2002-03-15 2003-09-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20060128720A1 (en) * 2002-03-21 2006-06-15 Kufe Donald W Inhibition of cell death responses induced by oxidative stress
AU2003216573A1 (en) * 2002-04-16 2003-10-27 Issam Moussa Drug eluting vascular stent and method of treating hyperproliferative vascular disease
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CN1652757B (zh) 2002-05-16 2012-02-08 诺瓦提斯公司 Edg受体结合剂在癌症中的应用
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt
EP1519727A1 (de) * 2002-06-28 2005-04-06 The Administrators of the Tulane Educational Fund 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamid zur behandlung von lungenfibrose
WO2004002963A1 (ja) * 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
AU2003252047A1 (en) * 2002-07-18 2004-02-09 Medtronic Ave Inc. Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
CA2492878A1 (en) * 2002-07-19 2004-01-29 Ludwig Institute For Cancer Research Enhancing the effect of radioimmunotherapy in the treatment of tumors
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス　アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド
BR0312873A (pt) * 2002-07-24 2005-06-28 Univ Cincinnati 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
CN100491374C (zh) 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
EP1551824B1 (de) * 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein-tyrosine-kinase-inhibitoren
GB0224455D0 (en) * 2002-10-21 2002-11-27 Novartis Ag Organic compounds
WO2004037261A1 (en) * 2002-10-25 2004-05-06 The Administrators Of The Tulane Educational Fund Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
JP2006513791A (ja) * 2003-04-04 2006-04-27 ベイコ テック リミテッド 血管用ステント
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0312086D0 (en) * 2003-05-27 2003-07-02 Novartis Ag Organic compounds
JP4776537B2 (ja) * 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
WO2004106326A1 (en) * 2003-06-02 2004-12-09 Hetero Drugs Limited Novel polymorphs of imatinib mesylate
EP1635815A4 (de) * 2003-06-03 2009-03-25 Beth Israel Hospital Verfahren und verbindungen zur behandlung von gefässstenose
AU2004273605B2 (en) * 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US7718676B2 (en) 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
JPWO2005063720A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
MY144177A (en) 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
EP1720853B2 (de) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmazeutische zusammensetzungen der 2-kristallform von imatinib-mesylat zur verwendung bei der behandlung von chronischer myelogener leukämie
CN1309719C (zh) * 2004-02-18 2007-04-11 陈国庆 苯氨基嘧啶衍生物及其用途
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MXPA06015148A (es) * 2004-07-01 2007-08-21 Netherlands Cancer Inst Combinacion que comprende un inhibidor de bcrp y 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida.
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CA2591321C (en) 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
EP2361624A1 (de) 2005-04-04 2011-08-31 AB Science Oxazolderivate und Ihre Anwendung als Tyrosinkinase Inhibitoren
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2430727C2 (ru) 2005-06-03 2011-10-10 Новартис Аг Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
ES2334933T3 (es) * 2005-08-15 2010-03-17 Siegfried Generics International Ag Comprimido recubierto o granulado que contiene una piridilpirimidina.
KR20080049766A (ko) * 2005-08-26 2008-06-04 노파르티스 아게 이마티니브 메실레이트의 델타 및 엡실론 결정 형태
SI2275103T1 (sl) 2005-11-21 2014-07-31 Novartis Ag mTor inhibitorji pri zdravljenju endokrinih tumorjev
KR20130141712A (ko) 2005-11-25 2013-12-26 노파르티스 아게 이마티니브 메실레이트의 ｆ, ｇ, ｈ, ｉ 및 ｋ 결정형
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CA2645633A1 (en) 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
RU2452492C2 (ru) 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
BRPI0702877A2 (pt) * 2006-04-27 2015-07-07 Ivax Pharmaceuticals S R O E Teva Pharmaceutical Usa Inc Formas polimórficas de mesilato de imatinib, processo para o novo preparo de novas formas cristalinas, amorfas e forma alfa, composições farmacêuticas correlatas, seus processos de preparo e uso
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
US20090317489A1 (en) 2006-05-09 2009-12-24 Hanspeter Nick Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
WO2008004944A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline form ii
WO2008004945A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline forms i and ii
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
PL2068938T3 (pl) 2006-09-22 2011-06-30 Novartis Ag Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
EP2009008A1 (de) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
US20080103305A1 (en) * 2006-10-26 2008-05-01 Macdonald Peter Process for the preparation of imatinib
WO2008070350A2 (en) 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
EP1920767A1 (de) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Schmelzverarbeitete Darreichungsform mit Imatinib
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CA2669531A1 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US8153792B2 (en) * 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
EP2491923A3 (de) 2007-02-15 2012-12-26 Novartis AG Kombinationen therapeutischer Wirkstoffe zur Krebsbehandlung
CN101265275B (zh) * 2007-02-16 2012-09-05 中国医学科学院药物研究所 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
CA2680249A1 (en) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories, Inc. Imatinib mesylate
US20080234286A1 (en) * 2007-03-20 2008-09-25 Chemagis Ltd. Stable amorphous imatinib mesylate and production process therefor
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2008150481A2 (en) * 2007-05-29 2008-12-11 Sicor Inc. Processes for the preparation of crystalline form beta of imatinib mesylate
EP2000139A1 (de) 2007-06-07 2008-12-10 Novartis AG Stabilisierte amorphe Formen von Imatinib Mesylat
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2268612B1 (de) 2008-03-24 2014-08-20 Novartis AG Matrix-metalloproteinaseinhibitoren auf arylsulfonamidbasis
CN102036955B (zh) 2008-03-26 2013-03-27 诺瓦提斯公司 脱乙酰酶b的异羟肟酸盐为基础的抑制剂
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CA2727737C (en) 2008-06-27 2016-08-23 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
DE102008031037A1 (de) 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Gleevec zur Anwedung in der Organtransplantation
EP3023426A1 (de) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2186514B1 (de) 2008-11-14 2016-06-29 Kinki University Behandlung von malignen Peripherienervmantel-Tumoren
US8697702B2 (en) 2008-12-01 2014-04-15 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
PE20120336A1 (es) 2008-12-18 2012-04-30 Novartis Ag Sal de hemi-fumarato del acido 1-[4-[1-(4-ciclohexil-3-triflouro-metil-benciloxi-imino)-etil)-2-etil-bencil]-azetidin-3-carboxilico
AU2009335887A1 (en) 2008-12-18 2011-06-30 Novartis Ag New salts
BRPI0922457A2 (pt) 2008-12-18 2015-12-15 Novartis Ag forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
ES2753874T3 (es) 2009-04-28 2020-04-14 Daiichi Sankyo Co Ltd Cristales de solvato novedosos
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
CA2773661A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
WO2011039782A1 (en) * 2009-09-29 2011-04-07 Ind-Swift Laboratories Limited Processes for preparing imatinib and pharmaceutically acceptable salts thereof
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
EP2496575B1 (de) 2009-11-04 2014-04-30 Novartis AG Heterocyclische sulfonamidderivate als mek-hemmer
BR112012012210B8 (pt) 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
WO2011070030A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
EP2552915B1 (de) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Verbindungen zur behandlung von hiv
WO2011130918A1 (zh) 2010-04-23 2011-10-27 上海百灵医药科技有限公司 一种伊马替尼的合成方法
EP2382976A1 (de) 2010-04-30 2011-11-02 Hiroshima University Verwendung von PDGF-R-Inhibitoren zur Behandlung der Lymphknotenmetastasen von Magenkrebs
EA022094B1 (ru) * 2010-06-16 2015-10-30 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма амидного соединения
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
EP2582681A1 (de) 2010-06-17 2013-04-24 Novartis AG Piperidinylsubstituierte 1,3-dihydro-benzoimidazol-2-ylidenaminderivate
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
MX2013001653A (es) 2010-08-11 2013-05-22 Synthon Bv Granulado farmaceutico que comprende mesilato de imatinib
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
RU2456280C2 (ru) * 2010-08-27 2012-07-20 Общество с ограниченной ответственностью "Химфармресурс" Кристаллическая n-модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил] бензамида метансульфоната, способ ее получения и фармацевтическая композиция на ее основе
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102477031B (zh) 2010-11-30 2015-07-15 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
TR201010618A2 (tr) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
JP2014500308A (ja) 2010-12-21 2014-01-09 ノバルティス アーゲー Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN102146073A (zh) * 2011-02-23 2011-08-10 江苏先声药物研究有限公司 一种伊玛替尼甲烷磺酸盐α晶型新的制备方法
CN102649785B (zh) * 2011-02-23 2015-08-19 江苏先声药物研究有限公司 一种伊玛替尼甲烷磺酸盐β晶型的制备方法
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013022552B1 (pt) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EP2691385A4 (de) 2011-03-31 2014-08-13 Ind Swift Lab Ltd Verbessertes verfahren zur herstellung von imatinib und seinem mesylatsalz
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
MX2013014398A (es) 2011-06-09 2014-03-21 Novartis Ag Derivados de sulfonamida heterociclicos.
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
CN103608349A (zh) 2011-06-27 2014-02-26 诺瓦提斯公司 四氢-吡啶并-嘧啶衍生物的固体形式和盐
ITMI20111309A1 (it) 2011-07-14 2013-01-15 Italiana Sint Spa Procedimento di preparazione di imatinib mesilato
CN102321070B (zh) * 2011-07-27 2013-05-22 江苏先声药物研究有限公司 反溶剂重结晶法制备伊玛替尼甲烷磺酸盐α晶型
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP6096205B2 (ja) 2011-11-01 2017-03-15 モッドジーン リミテッド ライアビリティ カンパニーＭｏｄｇｅｎｅ，Ｌｌｃ 低減されたタンパク質キナーゼ阻害を呈するイマチニブ誘導体の使用
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2604596A1 (de) 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphe von Imatinib
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
EP2794594A1 (de) 2011-12-22 2014-10-29 Novartis AG Chinolinderivate
WO2013096051A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
PL226174B1 (pl) 2011-12-30 2017-06-30 Inst Farm Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
CN102617549A (zh) * 2012-03-02 2012-08-01 瑞阳制药有限公司 甲磺酸伊马替尼β晶型的制备方法
IN2012DE00728A (de) 2012-03-13 2015-08-21 Fresenius Kabi Oncology Ltd
GB201204810D0 (en) 2012-03-20 2012-05-02 Pharos Pharmaceutical Oriented Services Ltd Pharmaceutical compositions
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
CN102617552A (zh) * 2012-04-06 2012-08-01 江南大学 一种制备α晶型甲磺酸伊马替尼的结晶方法
CN102633775B (zh) * 2012-04-06 2013-07-17 江南大学 一种甲磺酸伊马替尼α晶型的制备方法
JP2013216644A (ja) * 2012-04-11 2013-10-24 Takada Seiyaku Kk イマチニブメシル酸塩経口投与製剤
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
EP2861256B1 (de) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Zusammensetzungen zur behandlung von krebs und verfahren zur herstellung davon
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
EP2872142A1 (de) 2012-07-11 2015-05-20 Novartis AG Verfahren zur behandlung von gastrointestinalen stromatumoren
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US20140235631A1 (en) 2012-07-27 2014-08-21 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
CN103570677B (zh) * 2012-08-02 2017-03-01 广东东阳光药业有限公司 一种α晶型甲磺酸伊马替尼的制备方法
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
WO2014048377A1 (zh) 2012-09-28 2014-04-03 杭州本生药业有限公司 治疗肿瘤的组合药物及其应用
US9439903B2 (en) 2012-10-25 2016-09-13 Cadila Healthcare Limited Process for the preparation of amorphous imatinib mesylate
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2749271A1 (de) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimiertes Verfahren zur herstellung und pharmazeutische zusammensetzung von Imatinib
EP2749269A1 (de) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Verfahren zur Herstellung von Adsorbaten von Imatinib
EP2749557A1 (de) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Verfahren zur Herstellung von alpha-Polymorphe Form von Imatinib Mesylat aus IPA and THF-Solvaten von Imatinib Mesylat
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
DK2958943T3 (da) 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
GB201304699D0 (en) 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP2803353B1 (de) 2013-05-14 2018-05-23 Hetero Research Foundation Zusammensetzungen von Imatinib
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
CA2920059A1 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
AU2014336016B2 (en) 2013-10-17 2019-12-19 Sartar Therapeutics Ltd Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015110949A1 (en) 2014-01-22 2015-07-30 Novartis Ag Imatinib as cholesterol decreasing agent
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103800671B (zh) * 2014-02-11 2016-02-10 王思成 一种治疗阿弗他溃疡的中药制剂
CR20160425A (es) 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
US9399637B2 (en) 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
US9630944B2 (en) 2014-04-04 2017-04-25 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
CN104974133B (zh) * 2014-04-09 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种甲磺酸伊马替尼晶型及其制备方法
CN104055745A (zh) * 2014-06-11 2014-09-24 连云港杰瑞药业有限公司 一种甲磺酸伊马替尼片的制备方法
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US10385078B2 (en) 2014-10-21 2019-08-20 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MY190404A (en) 2015-03-10 2022-04-21 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN104817536A (zh) * 2015-04-14 2015-08-05 江苏豪森药业股份有限公司 适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
CN105503825B (zh) * 2015-12-16 2019-01-11 齐鲁天和惠世制药有限公司 一种甲磺酸伊马替尼β晶型的制备方法
EP3389712B1 (de) 2015-12-17 2024-04-10 Novartis AG Antikörpermoleküle gegen pd-1 und verwendungen davon
US10836745B2 (en) 2015-12-24 2020-11-17 Takeda Pharmaceutical Company Limited Cocrystal, production method thereof, and medicament containing cocrystal
EP3407874B1 (de) 2016-01-25 2024-05-22 KRKA, d.d., Novo mesto Schnell dispergierbare pharmazeutische zusammensetzung mit tyrosin-kinase-inhibitoren
JP7250312B2 (ja) 2016-03-25 2023-04-03 エービー サイエンス 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
EP3257499A1 (de) 2016-06-17 2017-12-20 Vipharm S.A. Verfahren zur herstellung von imatinib methansulfonat kapseln
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018039205A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
RU2019112860A (ru) 2016-09-27 2020-10-30 Серо Терапьютикс, Инк. Молекулы химерных интернализационных рецепторов
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
JP6691971B2 (ja) 2016-10-17 2020-05-13 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 慢性骨髄性白血病を治療又は寛解するための医薬組成物
PL3539138T3 (pl) 2016-11-11 2021-12-13 Curium Us Llc Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CA3073421A1 (en) 2017-09-26 2019-04-04 Daniel Mark COREY Chimeric engulfment receptor molecules and methods of use
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
CA3079422A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
EP3710006A4 (de) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituierte heteroarylverbindungen und verfahren zur verwendung
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3774906A1 (de) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimäre tim4-rezeptoren und verwendungen davon
MX2020010241A (es) 2018-03-28 2020-10-16 Cero Therapeutics Inc Composiciones de inmunoterapia celular y usos de las mismas.
WO2019191339A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3826988A4 (de) 2018-07-24 2023-03-22 Hygia Pharmaceuticals, LLC Verbindungen, derivate und analoga für krebs
EP3903828A4 (de) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited Kombination aus antikörper-arzneimittel-konjugat und kinaseinhibitor
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
EP4298114A1 (de) 2021-02-26 2024-01-03 Kelonia Therapeutics, Inc. Auf lymphozyten zielgerichtete lentivirale vektoren
EP4376874A1 (de) 2021-07-28 2024-06-05 Cero Therapeutics, Inc. Chimäre tim4-rezeptoren und verwendungen davon
CN114957206B (zh) * 2022-04-11 2024-02-27 中国药科大学 伊马替尼共晶及其制备方法
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887551A (en) 1964-11-04 1975-06-03 Glaxo Lab Ltd Crystalline forms of cephaloridine
GB1413516A (en) * 1972-10-06 1975-11-12 Leo Pharm Prod Ltd Crystalline pivaloyloxymethal d - -alpha- aminobenzylpenicillinate
US3905959A (en) 1973-05-07 1975-09-16 Pfizer Process for the manufacture of crystalline anhydrous ampicillin
US4061853A (en) 1975-12-09 1977-12-06 Ciba-Geigy Corporation Virtually solvent-free crystal form of the sodium salt of Cephacetril
US4351832A (en) 1980-04-18 1982-09-28 American Home Products Corporation 2-(Piperazinyl)-4-pyrimidinamines
US4512993A (en) 1983-07-25 1985-04-23 Sterling Drug Inc. 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
KR100330553B1 (ko) * 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
CA2201735A1 (en) * 1994-11-18 1996-05-30 The Upjohn Company A new physically stable solid form of a fluoroquinolone
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

Also Published As

Publication number Publication date
MY128664A (en) 2007-02-28
NZ502295A (en) 2001-12-21
BR9810920A (pt) 2000-08-15
NO331016B1 (no) 2011-09-12
MY129772A (en) 2007-04-30
IL133906A0 (en) 2001-04-30
JP3276359B2 (ja) 2002-04-22
IL168972A (en) 2006-08-01
HUP0003230A2 (hu) 2001-06-28
AU8975998A (en) 1999-02-10
AR016351A1 (es) 2001-07-04
US7151106B2 (en) 2006-12-19
NO20000227L (no) 2000-01-17
ES2209194T3 (es) 2004-06-16
NO20052755L (no) 2000-01-17
IL174732A0 (en) 2006-08-20
ZA986362B (en) 1999-01-22
PE97899A1 (es) 1999-10-29
US20070004746A1 (en) 2007-01-04
KR20010021950A (ko) 2001-03-15
CA2296604C (en) 2009-04-07
KR100450356B1 (ko) 2004-10-01
PL188348B1 (pl) 2005-01-31
US6894051B1 (en) 2005-05-17
PL338129A1 (en) 2000-09-25
US20050192284A1 (en) 2005-09-01
IL174082A (en) 2010-05-31
IL174082A0 (en) 2006-08-01
CZ298531B6 (cs) 2007-10-31
CZ2000149A3 (cs) 2000-05-17
TW491845B (en) 2002-06-21
ID24093A (id) 2000-07-06
NO319486B1 (no) 2005-08-22
HK1028599A1 (en) 2001-02-23
US20020115858A1 (en) 2002-08-22
RU2208012C2 (ru) 2003-07-10
US7544799B2 (en) 2009-06-09
CN1264375A (zh) 2000-08-23
JP2001510192A (ja) 2001-07-31
NO20000227D0 (no) 2000-01-17
SK432000A3 (en) 2000-06-12
NO20052755D0 (no) 2005-06-07
CN1134430C (zh) 2004-01-14
HUP0003230A3 (en) 2002-01-28
DE69818674D1 (de) 2003-11-06
ATE251152T1 (de) 2003-10-15
PT998473E (pt) 2004-02-27
HU230185B1 (hu) 2015-09-28
EP0998473B1 (de) 2003-10-01
DE69818674T2 (de) 2004-08-12
AU740713B2 (en) 2001-11-15
SK287276B6 (sk) 2010-05-07
IL133906A (en) 2006-07-05
TR200000060T2 (tr) 2000-09-21
US20060030568A1 (en) 2006-02-09
EP0998473A1 (de) 2000-05-10
SK286551B6 (sk) 2008-12-05
CA2296604A1 (en) 1999-01-28
WO1999003854A1 (en) 1999-01-28
CO4940418A1 (es) 2000-07-24
AR043266A2 (es) 2005-07-27

Similar Documents

Publication Publication Date Title
DK0998473T3 (da) Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse
DK1038008T3 (da) Fremgangsmåde til fremstilling af EGIII-lignende enzymer
DK1194226T3 (da) Apparat til forhydrolyse af biomasse samt dets anvendelse
DK0881495T3 (da) Kontrol af diabetes
DK1032565T3 (da) Fremgangsmåde til fremstilling af derivater af taxoid-klassen
DK1036794T3 (da) 2-Aryl-8-oxodihydropurinderivater, fremgangsmåde til fremstilling af samme, medicinske præparater indeholdende samme og mellemprodukter deraf
EE200000007A (et) Meetod ja seade telefoni kutsungisignaali juhtimiseks
DK1140824T3 (da) Fremgangsmåde til fremstilling af 3-alkanoyl- og 3-alkylindoler
FI103463B1 (fi) Tietokone ja menetelmä tietokoneen käyttämiseksi
DK0831098T3 (da) Mellemprodukter og fremgangsmåde til fremstilling af olanzapin
IT1293469B1 (it) Occhiali perfezionati
NO993298D0 (no) Ny fremgangsmÕte
DK0805797T3 (da) Fremgangsmåde til fremstilling af N-aryl- og N-hetarylhydroxylaminer
DK1027315T3 (da) Fremgangsmåde til fremstilling af n-butanol
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK1017910T3 (da) Element og system til tagbeklædning samt anvendelse af elementet
FI960377A0 (fi) Lämpöstabiileja polarisaattoreita
NO995796D0 (no) Ny fremgangsmåte
DK0927766T3 (da) Enzymatisk fremgangsmåde til fremstilling af (S)-cyanhydriner
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DK0951561T3 (da) Enzymatiske fremgangsmåder til fremstilling af (S)-cyanhydriner
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
DK0905128T3 (da) Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater
DK1036319T3 (da) Fremgangsmåde til opnåelse af L-dihydroorotsyre og anvendelse deraf